BioInvent Release: Recruitment of Patients Completed in Phase II Study with BI-204
3/2/2012 6:31:03 AM
LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (OMXS: BINV) and its collaborator Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease. BioInvent expects to publicly release top-line data from the study in Q3 2012.
comments powered by